HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bromocriptine Mesylate

HCID 31100
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
22260-51-1
Standard SMILES
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O
InChIKey
NOJMTMIRQRDZMT-GSPXQYRGSA-N
Molecular formula
C33H44BrN5O8S
Average molar mass
750.7 g/mol
Monoisotopic mass
749.2094

Overview

Bromocriptine methanesulfonate is a methanesulfonate salt. It has a role as an antiparkinson drug. It contains a bromocriptine.

Names & identifiers

Preferred name
Bromocriptine Mesylate
IUPAC
(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
English name
Bromocriptine mesylate
Molecular formula
C33H44BrN5O8S
Molecular weight
750.7

Names & synonyms

BROMOCRIPTINE MESYLATE22260-51-1Bromocriptine mesilatePravidelCyclosetBagrenBromocriptine methanesulfonateCB-154 mesylateCb-154 mesilate2-Bromo-alpha-ergocryptine mesylateDTXSID6020197FFP983J3OD
Show more names
BCTBRCBromocryptine mesylateBromocriptine-13C-d3 MesylateBromocriptine Mesylate (150 mg)cb-154Serono-Bagren
2-Bromoergocryptine MesylateNSC-755915DTXCID00197CHEBI:3182Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-Mesylate, BromocriptineRefChem:564242 Bromoergocryptine Mesylate

Database identifiers

CAS
22260-51-1
PubChem CID
31100
DTXSID
DTXSID6020197
ChEMBL

Properties

Computed structural properties

Topological polar surface area
181 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
9
Rotatable bonds
5
Heavy atoms
48
Formal charge
0
Complexity
1,320

Experimental & physicochemical properties

Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Dopamine Agonists; Ergot Alkaloids

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section244.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
192 · 192-196° (dec)
alpha
20 · D20 +95° (c = 1 in methanol-methylene chloride)
storage temp.
2 · 2-8°C
solubility
2 O: · H2O: 0.8 mg/mL
form
solid
pka
4.9 · 4.90(at 25℃)
color
white
optical activity
20 · [α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)
Water Solubility
2 O: · H2O: 0.8mg/mLethanol: 23mg/mL
Merck

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (45.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P273, P280, P301+P317, P304+P340, P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 11 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationBromocriptine mesylate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.)-, monomethanesulfonate (salt): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (45.5%)

Toxicology

Treatment · 1 item

Treatment of overdose consists of removal of the drug by emesis (if conscious), gastric lavage, activated charcoal, or saline catharsis. Careful supervision and recording of fluid intake and output is essential. Hypotension should be treated by placing the patient in the Trendelenburg position and administering I.V. fluids. If satisfactory relief of hypotension cannot be achieved by using the above measures to their fullest extent, vasopressors should be considered. (L1827)

Health Effects · 1 item

A slight hypotensive effect may accompany bromocriptine treatment. Few cases of cerebrospinal fluid rhinorrhea have been reported in patients receiving bromocriptine for treatment of large prolactinomas. Bromocriptine use has been associated with causing or worsening psychotic symptoms and fibrosis of multiple organs. Ingestion of ergoline alkaloids is known to cause the disease ergotism. Ergotism occurs in two forms, gangrenous and convulsive, likely depending on the different kinds and amounts of ergoline alkaloids present. (A2913, L1827, L1934)

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion. Route of Elimination: Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney. Half Life: 2-8 hours

FDA Pharmacological Classification · 2 items

BROMOCRIPTINE MESYLATE

Ergot Derivative [EPC]; Ergolines [CS]

MeSH Pharmacological Classification · 3 items

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.

Drugs that bind to and activate dopamine receptors.

Uses & manufacturing

Uses · 1 item

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. Bromocriptine is a semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion and is used in the treatment of pituitary tumors, Parkinson's disease (PD),Hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. Ergoline alkaloids occurs in various species of vines of the Convolvulaceae (morning glory) family and in some species of lower fungi. (L1918, L1934)

Related reactions

1 records
New reaction record
HRID 729201 reaction equation
HRID 729201As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEMBL1200503
ChEBI
CHEBI:3182
UNII
FFP983J3OD
EC Number
244-881-1
13 · 13,1400
BRN
4115238 · 4115238
Stability
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months
InChIKey
NOJMTMIRQRDZMT-JGYCFGIMSA-N
SMILES
N12[C@@H](CC(C)C)C(N3CCC[C@@]3([H])[C@]1(O)O[C@@](C(C)C)(NC(=O)[C@H]1CN(C3CC4=C(NC5C=CC=C(C4=5)C3=C1)Br)C)C2=O)=O.S(=O)(=O)(O)C |&1:1,11,13,16,23,r|
CAS DataBase Reference
22260 · 22260-51-1(CAS DataBase Reference)
FDA UNII
983 J3OD · FFP983J3OD
NCI Drug Dictionary
bromocriptine mesylate
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07,GHS09
Signal word
Warning
Hazard statements
302 · H302-H410
Precautionary statements
273 · P273-P301+P312+P330
PPE
95 · Eyeshields, Gloves, type N95 (US)
Hazard Codes
Xn
Risk Statements
20 · 20/21/22
Safety Statements
22 · 22-24/25-36
RIDADR
3077 · UN 3077 9 / PGIII
WGK Germany
3 · 3
RTECS
1595000 · KE1595000
F
3 · 3-10
HS Code
29396900 · 29396900
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralAquatic · Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1
Toxicity
50 in · LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
Exposure Routes · 1 item

Oral (L1934). Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.

Toxicity Summary · 1 item

The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Ergoline alkaloids have been shown to have the significant affinity towards the 5-HT1 and 5-HT2 serotonin receptors, D1 and D2 dopamine receptors, and alpha-adrenergic receptors. This can result in a number of different effects, including vasoconstriction, convulsions, and hallucinations. Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum. (A2914, A2915, A2916, A2941)

Signs and Symptoms · 1 item

Side effects of bromocriptine include nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion, constipation, diarrhea and drowsiness. Convulsive ergotism can cause painful seizures and spasms, diarrhea, paresthesias, itching, headaches, nausea and vomiting. Usually the gastrointestinal effects precede the central nervous system effects. As well as seizures there can be hallucinations and mental effects including mania or psychosis. Gangrenous ergotism causes dry gangrene as a result of vasoconstriction induced in the more poorly vascularized distal structures, such as the fingers and toes. Symptoms include desquamation, weak periphery pulse, loss of peripheral sensation, edema and ultimately the death and loss of affected tissues. (L1920, L1827)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bromocriptine mesylate

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

F
3-10
PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
rtecs
KE1595000
ridadr
UN 3077 9 / PGIII
hs_code
29396900
Toxicity
LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)
risk_code
20/21/22
Signal word
Warning
Symbol(GHS)
GHS07,GHS09
hazard_code
Xn
safety_code
22-24/25-36
Storage Class
11 - Combustible Solids
Hazard statements
H302-H410
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1
Precautionary statements
P273-P301+P312+P330
Applications · 5 items

DescriptionBromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.

UsesDopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.

Uses2-Bromo-α-Ergocryptine is a dopamine receptor agonist. 2-Bromo-α-Ergocryptine is a derivative of the ergotoxin group of ergot alkaloids. 2-Bromo-α-Ergocryptine is a prolactin inhibitor; antiparkinsoni an.

Uses2-Bromo-α-ergocryptine methanesulfonate salt has been used:as D2 agonist in bird zebra finchesfor Prl secretion inhibitor in micefor the inhibition of motility in planaria worm

General DescriptionBromocriptine mesylate,(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate(Parlodel), is a white solid soluble in ethanol and slightly solublein water (pKa’s=6.6 and 15). Bromocriptine is rapidlyabsorbed after oral administration and it has low systemicbioavailability because of its extensive first-pass metabolism.Bromocriptine enters the brain quickly with a half-lifefor uptake into the brain of approximately 0.3 hours; 8% ofthe drug crosses the BBB.The metabolites are excreted primarilyin the bile and feces. The high first-pass hepatic metabolismimplies an increased risk of drug interactions.Concomitant administration with the DA antagonists, metoclopramide,or domperidone may aggravate parkinsoniansymptoms and induce extrapyramidal side effects (EPS).Other drugs that may interact with bromocriptine are highlyplasma protein–bound drugs (e.g., warfarin, increased dyskinesiacaused by bromocriptine); macrolides antibacterials(enhanced dopaminergic effects); and caffeine (elevation inplasma bromocriptine concentrations). The combination oflevodopa/AADC inhibitors with bromocriptine permits a reductionof the dose of levodopa. Thus, the side effects oflevodopa are decreased, resulting in a more continuous stimulationof DA receptors.

Upstream & downstream products

Upstream raw materials

α-ErgocryptineN-Bromosuccinimide

Additional notes

DefinitionChEBI: Bromocriptine methanesulfonate is a methanesulfonate salt. It has a role as an antiparkinson drug. It contains a bromocriptine.